Our understanding of the mechanisms mediating or moderating the placebo response to
medicines has grown substantially over the past decade and offers the opportunity to …

The tremendous advances achieved in the understanding of cancer biology have delivered
unprecedented progress in molecularly targeted cancer therapy in the past decade. The fast …

Historical controls (HCs) can be used for model parameter estimation at the study design
phase, adaptation within a study, or supplementation or replacement of a control arm …

This Perspective highlights biomarkers that are expressed as a consequence of cancer
development and progression. We focus on those biomarkers that are most relevant for …

The life sciences have never been an easy industry, and they are about to become even
more treacherous to navigate. New technologies speed up innovation, new competitors …

Orphan drug incentives have stimulated research into diseases with significant unmet
medical need. Although the targeting of orphan diseases is seen by industry as an attractive …

Important objectives in the development of stratified medicines include the identification and
confirmation of subgroups of patients with a beneficial treatment effect and a positive benefit …

Background Personalized medicine is a growing area of research which aims to tailor the
treatment given to a patient according to one or more personal characteristics. These …

Drugs are approved by regulatory agencies on the basis of their assessment of whether the
available evidence indicates that the benefits of the drug outweigh its risks. In recent years …

In the field of oncology, clinical molecular diagnostics and biomarker discoveries are
constantly advancing as the intricate molecular mechanisms that transform a normal cell into …